Biosimilar Education and Outreach

The Food and Drug Administration is forecasting continued contract support for comprehensive, data-driven education and outreach initiatives aimed at enhancing awareness and understanding of biosimilars among patients, healthcare providers, and key stakeholders. The initiative will focus on delivering targeted activities that inform and influence public and professional perception through evidence-based strategies, ensuring accurate and consistent messaging about biosimilar safety, efficacy, and value in the healthcare ecosystem. This effort is designed to bridge knowledge gaps and promote informed decision-making across the U.S. healthcare landscape. The opportunity is classified under NAICS code 561499 and is managed by the FDA’s Center for Drug Evaluation and Research. While the solicitation number and set-aside details are not yet available, the contract will be administered through the agency’s acquisition office, with the Program Point of Contact listed as the Cder Acquisition Liaison at cderacquisitions@fda.hhs.gov. The Contracting Officer designation is pending, and performance location details have not been specified. The forecasted posting date is May 25, 2026, and further details will be made available through the official OSDBU opportunity forecast portal.